Pembrolizumab (Pembro) plus enzalutamide (Enz) in metastatic castration resistant prostate cancer (mCRPC): Extended follow up

Authors :: Rachel Slottke
Tomasz M. Beer
Charles G. Drake
Joshi J. Alumkal
Mary A. Wood
George Thomas
Amy E. Moran
Julie N. Graff
Reid F. Thompson
Source :: Journal of Clinical Oncology. 36:5047-5047
Publication Year :: 2018
Publisher :: American Society of Clinical Oncology (ASCO), 2018.
Abstract: 5047Background: Anti-PD1 treatment with Pembro is a promising treatment strategy in many solid tumors. Here, we report clinical outcomes of adding Pembro to men with mCRPC progressing on Enz. Metho...

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
business.industry
030232 urology & nephrology
Pembrolizumab
Castration resistant
medicine.disease
03 medical and health sciences
Prostate cancer
chemistry.chemical_compound
0302 clinical medicine
chemistry
030220 oncology & carcinogenesis
Internal medicine
Medicine
Enzalutamide
Treatment strategy
business

Full Text Access

Tools